Abstract
Multiparametric MRI (mpMRI) plays a critical role in the detection, staging and risk stratification of prostate cancer (PCa). There are two widely accepted structured reporting systems used for interpretation of mpMRI of the prostate - PI-RADS v2.1 and Likert. Both these systems demonstrate good diagnostic performance with high cancer detection rates however have key conceptual differences. In this commentary, the authors highlight the individual strengths and areas of potential improvement as well as emphasize the need for continued clinical validation for these interpreting and reporting systems.